Cerebral Microvascular DysfunctionPROCESSNCT06579677
PRospective Observation on CErebral microvaScular Structure and Function
An observational study of Cerebral Microvascular Dysfunction and Cerebral Small Vessel Diseases, run by Beijing Tiantan Hospital at 2 sites in China.
Trial summary
This is a population-based prospective cohort study, aiming to assess the prevalence, distributional characteristics, and dynamic change of cerebral small vessel dysfunction in a Chinese community population using advanced vascular imaging techniques; meanwhile to investigate the effect of vascular risk factors on… Read more about this study
- Who is it for?
- Ages 50 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Cerebral Microvascular Dysfunction, Cerebral Small Vessel Diseases, Cognitive Dysfunction
- What is being tested?
- Without any intervention
- How many people
- 3,500 participants
- Where
- 2 sitesChina
- Study dates
- 18 Oct 2024to Oct 2032
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: The target population of the PROCESS study is community-dwelling adults aged 50-75 years based on cluster sampling from villages and communities of Daxing District, Beijing. The steering committee will attempt to ensure population representativeness of the sample. These selected villages and communities will be living communities (not occupational communities) with little population migration.
Who may be able to join
- Community-dwelling adults aged 50-75 years;
- Registered Beijing household residents or residents who can be followed up stably in their own communities for a long period;
- Subjects with written informed consents.
Who cannot join
- Residents with moderate to severe disabilities (MRS ≥3), mental illness, stroke, dementia, and other serious neurological disorders (e.g., encephalitis, Parkinson's disease, epilepsy, brain tumors, and rare genetic diseases of the nervous system);
- Life expectancy of ≤4 years due to serious diseases such as end-stage cancer;
- Contraindications to magnetic resonance imaging such as implanted devices (e.g., pacemakers, defibrillators, and others);
- Residents who are participating in other studies.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
China2 sites, 2 recruiting
- Not yet recruiting
Beijing Tiantan Hospital
Beijing, Beijing Municipality, 100070
Yilong Wang, M.D., 0086-010-59975029, yilong528@aliyun.com
yilong wang, M.D.
- Recruiting
Beijing Daxing District People Hospital
Beijing, Beijing Municipality, 102600
Ying Zhang, M.D., 0086-010-60283383, zhangying1838@gmail.com
About this study
Official title: PRospective Observation on CErebral microvaScular Structure and Function (PROCESS): a Population-based Prospective Cohort Study
This is a population-based prospective cohort study, aiming to assess the prevalence, distributional characteristics, and dynamic change of cerebral small vessel dysfunction in a Chinese community population using advanced vascular imaging techniques; meanwhile to investigate the effect of vascular risk factors on cerebral small vessel dysfunction, cardiovascular and cerebrovascular diseases, cognitive dysfunction, and mortality.
Read the detailed description
Brain health is defined as normal brain structure, function and social adaptation and the absence of major brain diseases. Brain health is a lifespan-wide process that can be objectively measured and subjectively perceived and is determined by socio-psycho-biological factors. Currently, neurological disorders are the first cause of healthy life lost and the second leading cause of death globally, with nearly 9 million people dying each year from brain-related diseases.
Prevention of major brain diseases, including stroke and dementia, is first and foremost for brain health management. Notably, cerebral small vessel dysfunction may be an earlier pathologic change for the aforementioned major brain diseases. Cerebral small vessel dysfunction includes increased blood-brain barrier permeability, altered neurovascular coupling, decreased cerebral perfusion, decreased cerebral autoregulation, decreased cerebrovascular reactivity, and altered cerebral resting blood flow. Previous studies have shown that the prevalence of cerebral small vessel dysfunction was as high as 40% to 70% in people with illness but data from the general population remain scarce. Vascular risk factors such as aging, hypertension, diabetes, obesity, dyslipidemia, and insulin resistance have been known as important risk factors for the development of major brain diseases. Whereas, it is unclear whether vascular risk factors will cause these brain diseases through affecting cerebral small vessel function.
Thus, this prospective cohort study aims to assess the prevalence, distributional characteristics, and dynamic change of cerebral small vessel dysfunction, and to investigate the effect of vascular risk factors on cerebral small vessel dysfunction, cardiovascular and cerebrovascular diseases, cognitive dysfunction, and mortality in a Chinese community population.
In this study, a total of 3500 participants aged 50 to 75 years from villages and communities of Daxing District, Beijing will be enrolled using cluster sampling method. All the participants will be interviewed at baseline and followed up for 8 years. Baseline data will be collected through face-to-face interviews by trained interviewers using a standardized questionnaire. Baseline data include demographics, lifestyle, physical activity, medical history, cardiovascular risk factors, dietary habits, medication use, sleep status, novel coronavirus infection. Cognitive function assessment and neuropsychiatric examination will be performed based on various scales such as the Montreal Cognitive Assessment (MoCA) Scale and Mini-Mental State Examination (MMSE) Scale.
Additionally, heart function will be tested using electrocardiogram and color ultrasound. Peripheral vascular examination will be performed to measure ankle-brachial index. Fundus examination will be performed by trained ophthalmologists. Gait and eye movement examination will be performed by trained staff. The body composition will be tested using a body composition analyzer.
The samples of fasting blood, morning urine, feces, oral plaque bacteria will be collected at baseline to test genetic and metabolomic markers. An oral glucose tolerance test will be performed to measure blood glucose, insulin, and C-peptide.
Brain magnetic resonance imaging (MRI) examination will be performed to detect CSVD imaging markers, craniocarotid plaque and stenosis, neurovascular coupling, and cerebral perfusion. The sequences of brain MRI included 3D-T1, 3D-T2, 3D-FLAIR, DWI, HR-MRA, SWI, resting-state fMRI, DTI, ASL, etc. All MRI scans will be conducted on 3.0 T scanners. Imaging data will be saved in digital imaging and communications in medicine (DICOM) format on discs and be analyzed at the Imaging Research Center of Beijing Tiantan Hospital. Transcranial Doppler ultrasonography will be used to detect cerebral autoregulation and cerebral resting blood flow. Carotid ultrasound will be used to measure carotid artery diameter, carotid intramedullary thickness, carotid systolic maximal flow velocity, carotid end-diastolic velocity, pulsatility index, vascular resistance index, carotid artery plaque, carotid artery stenosis, and blood flow velocity.
Routine follow-up will be performed each year to collect cardio-/cerebrovascular diseases and death after enrollment. A further face-to-face interview will be performed at 2, 4, 6, 8 years to collect the data of brain MRI scanning, transcranial Doppler ultrasonography, and cognitive impairment. Meanwhile, standard clinical and neuropsychologic examination will be conducted using the same scale as that at baseline. Fasting blood and morning urine samples will be collected at each follow-up visit following same protocol as that at baseline.
The protocol of this study has been approved by the Ethics Committee of Beijing Tiantan Hospital. All participants will provide written informed consents before entering the study.
- Conditions
- Cerebral Microvascular Dysfunction, Cerebral Small Vessel Diseases, Cognitive Dysfunction, Cerebrovascular Disorders, Cardiovascular Diseases, Population
- Being tested
- Without any intervention
- Medical subject headings
- Cerebral Small Vessel Diseases, Cognitive Dysfunction, Cerebrovascular Disorders, Cardiovascular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Without any interventionOther
No interventions will be performed.
| Study group | Role | What they receive |
|---|---|---|
| PROCESS Cohort | Not described Receives: Other: Without any intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cerebral small vessel disease
Cerebral small vessel disease will be evaluated using 3.0 T MRI based on imaging markers of asymptomatic cerebral infarction, cerebral microbleeds, lacunar, white matter hyperintensity, enlarged perivascular space, and cerebral atrophy.
Measured: 2024-09 to 2032-09
Neurovascular coupling
Neurovascular coupling is one of cerebral small vessel function indicators and will be measured by 3.0 T MRI.
Measured: 2024-09 to 2032-09
Cerebral perfusion
Cerebral perfusion is one of cerebral small vessel function indicators and will be measured by 3.0 T MRI.
Measured: 2024-09 to 2032-09
Cerebral autoregulation
Cerebral autoregulation is one of cerebral small vessel function indicators and will be measured by transcranial Doppler ultrasonography.
Measured: 2024-09 to 2032-09
Cerebral resting blood flow
Cerebral resting blood flow is one of cerebral small vessel function indicators and will be measured by transcranial Doppler ultrasonography.
Measured: 2024-09 to 2032-09
Secondary outcomes (9)
Composite vascular events
Composite vascular events include non-fatal acute myocardial infarction, non-fatal acute stroke (cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage), hospitalization for vascular reasons (including unstable angina pectoris, transient ischemic attack, and other ischemic vascular events), and vascular deaths (fatal infarcts, fatal strokes, and other vascular deaths). These events will be collected by self-report and confirmed by reviewing their medical records.
Measured: 2024-09 to 2032-09
Cognitive impairment measured by the Montreal Cognitive Assessment (MoCA) scale
Measured: 2024-09 to 2032-09
Cognitive impairment measured by the Mini-Mental State Examination (MMSE) scale
Measured: 2024-09 to 2032-09
All causes of death
All causes of death includes cardiovascular death and noncardiovascular death.
Measured: 2024-09 to 2032-09
Atherosclerotic plaque in retinal arteries.
Measured: 2024-09 to 2032-09
Atherosclerotic plaque in craniocarotid arteries.
Measured: 2024-09 to 2032-09
Other vascular events
Other vascular events include peripheral vascular disease, subclavian steal syndrome and systemic thromboembolic events.
Measured: 2024-09 to 2032-09
Vascular interventions
Vascular interventions such as arterial bypass, balloon dilatation, stent implantation, carotid endarterectomy, mechanical thrombolysis and ischemic amputation. These events will be collected by self-report and confirmed by reviewing their medical records.
Measured: 2024-09 to 2032-09
Mean blood flow velocity in arteries
Mean blood flow velocities in the distal common carotid artery, internal carotid artery bulb, proximal-distal internal carotid artery, and vertebral artery will be measured by pulsed Doppler ultrasound.
Measured: 2024-09 to 2032-09
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Aug 2024
- Study start18 Oct 2024
- Primary completionMar 2032 (estimated)
- Study completionOct 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cerebral Microvascular DysfunctionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 3,500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Beijing Tiantan Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- People's Hospital of Beijing Daxing District
- Responsible party
- Principal investigator, yilong Wang, Beijing Tiantan Hospital
- Investigators
- Yilong Wang, MD, PhD, Principal investigator, Beijing Tiantan Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06579677
- Sponsor's protocol ID
- KY2024-179-02
- Acronym
- PROCESS
- Status last verified
- Jan 2025
- First submitted
- 23 Aug 2024
- Last updated
- 6 Jan 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The data can be requested through the website of the data management system (http://paper.ncrcnd.org.cn/) or by sending email to the principal investigators.
Study at a glance
From the registry record, last updated by the sponsor on 6 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- PRospective Observation on CErebral microvaScular Structure and Function (PROCESS): a Population-based Prospective Cohort Study
- ClinicalTrials.gov ID
- NCT06579677
- Acronym / sponsor ID
- PROCESS / KY2024-179-02
- Conditions
- Cerebral Microvascular Dysfunction, Cerebral Small Vessel Diseases, Cognitive Dysfunction, Cerebrovascular Disorders, Cardiovascular Diseases, Population
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 3,500 participants (estimated)
- Lead sponsor
- Beijing Tiantan HospitalUniversity, hospital or other
- Collaborators
- People's Hospital of Beijing Daxing District
- Study start
- 18 Oct 2024 (actual)
- Primary completion
- Mar 2032 (estimated)
- Study completion
- Oct 2032 (estimated)
- First posted
- 30 Aug 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a population-based prospective cohort study, aiming to assess the prevalence, distributional characteristics, and dynamic change of cerebral small vessel dysfunction in a Chinese community population using advanced vascular imaging techniques; meanwhile to investigate the effect of vascular risk factors on cerebral small vessel dysfunction, cardiovascular and cerebrovascular diseases, cognitive dysfunction, and mortality.
Detailed description
Brain health is defined as normal brain structure, function and social adaptation and the absence of major brain diseases. Brain health is a lifespan-wide process that can be objectively measured and subjectively perceived and is determined by socio-psycho-biological factors. Currently, neurological disorders are the first cause of healthy life lost and the second leading cause of death globally, with nearly 9 million people dying each year from brain-related diseases.
Prevention of major brain diseases, including stroke and dementia, is first and foremost for brain health management. Notably, cerebral small vessel dysfunction may be an earlier pathologic change for the aforementioned major brain diseases. Cerebral small vessel dysfunction includes increased blood-brain barrier permeability, altered neurovascular coupling, decreased cerebral perfusion, decreased cerebral autoregulation, decreased cerebrovascular reactivity, and altered cerebral resting blood flow. Previous studies have shown that the prevalence of cerebral small vessel dysfunction was as high as 40% to 70% in people with illness but data from the general population remain scarce. Vascular risk factors such as aging, hypertension, diabetes, obesity, dyslipidemia, and insulin resistance have been known as important risk factors for the development of major brain diseases. Whereas, it is unclear whether vascular risk factors will cause these brain diseases through affecting cerebral small vessel function.
Thus, this prospective cohort study aims to assess the prevalence, distributional characteristics, and dynamic change of cerebral small vessel dysfunction, and to investigate the effect of vascular risk factors on cerebral small vessel dysfunction, cardiovascular and cerebrovascular diseases, cognitive dysfunction, and mortality in a Chinese community population.
In this study, a total of 3500 participants aged 50 to 75 years from villages and communities of Daxing District, Beijing will be enrolled using cluster sampling method. All the participants will be interviewed at baseline and followed up for 8 years. Baseline data will be collected through face-to-face interviews by trained interviewers using a standardized questionnaire. Baseline data include demographics, lifestyle, physical activity, medical history, cardiovascular risk factors, dietary habits, medication use, sleep status, novel coronavirus infection. Cognitive function assessment and neuropsychiatric examination will be performed based on various scales such as the Montreal Cognitive Assessment (MoCA) Scale and Mini-Mental State Examination (MMSE) Scale.
Additionally, heart function will be tested using electrocardiogram and color ultrasound. Peripheral vascular examination will be performed to measure ankle-brachial index. Fundus examination will be performed by trained ophthalmologists. Gait and eye movement examination will be performed by trained staff. The body composition will be tested using a body composition analyzer.
The samples of fasting blood, morning urine, feces, oral plaque bacteria will be collected at baseline to test genetic and metabolomic markers. An oral glucose tolerance test will be performed to measure blood glucose, insulin, and C-peptide.
Brain magnetic resonance imaging (MRI) examination will be performed to detect CSVD imaging markers, craniocarotid plaque and stenosis, neurovascular coupling, and cerebral perfusion. The sequences of brain MRI included 3D-T1, 3D-T2, 3D-FLAIR, DWI, HR-MRA, SWI, resting-state fMRI, DTI, ASL, etc. All MRI scans will be conducted on 3.0 T scanners. Imaging data will be saved in digital imaging and communications in medicine (DICOM) format on discs and be analyzed at the Imaging Research Center of Beijing Tiantan Hospital. Transcranial Doppler ultrasonography will be used to detect cerebral autoregulation and cerebral resting blood flow. Carotid ultrasound will be used to measure carotid artery diameter, carotid intramedullary thickness, carotid systolic maximal flow velocity, carotid end-diastolic velocity, pulsatility index, vascular resistance index, carotid artery plaque, carotid artery stenosis, and blood flow velocity.
Routine follow-up will be performed each year to collect cardio-/cerebrovascular diseases and death after enrollment. A further face-to-face interview will be performed at 2, 4, 6, 8 years to collect the data of brain MRI scanning, transcranial Doppler ultrasonography, and cognitive impairment. Meanwhile, standard clinical and neuropsychologic examination will be conducted using the same scale as that at baseline. Fasting blood and morning urine samples will be collected at each follow-up visit following same protocol as that at baseline.
The protocol of this study has been approved by the Ethics Committee of Beijing Tiantan Hospital. All participants will provide written informed consents before entering the study.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| PROCESS Cohort | – | Other: Without any intervention |
Who may qualify
- Ages
- 50 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The target population of the PROCESS study is community-dwelling adults aged 50-75 years based on cluster sampling from villages and communities of Daxing District, Beijing. The steering committee will attempt to ensure population representativeness of the sample. These selected villages and communities will be living communities (not occupational communities) with little population migration.
Key inclusion criteria (3 listed)
- Community-dwelling adults aged 50-75 years;
- Registered Beijing household residents or residents who can be followed up stably in their own communities for a long period;
- Subjects with written informed consents.
Key exclusion criteria (4 listed)
- Residents with moderate to severe disabilities (MRS ≥3), mental illness, stroke, dementia, and other serious neurological disorders (e.g., encephalitis, Parkinson's disease, epilepsy, brain tumors, and rare genetic diseases of the nervous system);
- Life expectancy of ≤4 years due to serious diseases such as end-stage cancer;
- Contraindications to magnetic resonance imaging such as implanted devices (e.g., pacemakers, defibrillators, and others);
- Residents who are participating in other studies.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Without any interventionNo interventions will be performed. | Other | PROCESS Cohort |
Primary outcome
Cerebral small vessel disease
Time frame: 2024-09 to 2032-09
Cerebral small vessel disease will be evaluated using 3.0 T MRI based on imaging markers of asymptomatic cerebral infarction, cerebral microbleeds, lacunar, white matter hyperintensity, enlarged perivascular space, and cerebral atrophy.
Neurovascular coupling
Time frame: 2024-09 to 2032-09
Neurovascular coupling is one of cerebral small vessel function indicators and will be measured by 3.0 T MRI.
Cerebral perfusion
Time frame: 2024-09 to 2032-09
Cerebral perfusion is one of cerebral small vessel function indicators and will be measured by 3.0 T MRI.
Cerebral autoregulation
Time frame: 2024-09 to 2032-09
Cerebral autoregulation is one of cerebral small vessel function indicators and will be measured by transcranial Doppler ultrasonography.
Cerebral resting blood flow
Time frame: 2024-09 to 2032-09
Cerebral resting blood flow is one of cerebral small vessel function indicators and will be measured by transcranial Doppler ultrasonography.
9 secondary outcomes
Composite vascular events
Time frame: 2024-09 to 2032-09
Cognitive impairment measured by the Montreal Cognitive Assessment (MoCA) scale
Time frame: 2024-09 to 2032-09
Cognitive impairment measured by the Mini-Mental State Examination (MMSE) scale
Time frame: 2024-09 to 2032-09
All causes of death
Time frame: 2024-09 to 2032-09
Atherosclerotic plaque in retinal arteries.
Time frame: 2024-09 to 2032-09
Atherosclerotic plaque in craniocarotid arteries.
Time frame: 2024-09 to 2032-09
Other vascular events
Time frame: 2024-09 to 2032-09
Vascular interventions
Time frame: 2024-09 to 2032-09
Mean blood flow velocity in arteries
Time frame: 2024-09 to 2032-09
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Jan 2025.
- Individual participant dataSharing planned: Yes. The data can be requested through the website of the data management system (http://paper.ncrcnd.org.cn/) or by sending email to the principal investigators.
Related trials for Cerebral Microvascular Dysfunction
Not yet recruitingPhase 4
Hormone thERapy Effects on BRAin-HEART Health During the Menopausal Transition
Menopause, Perimenopause
Enrolling by invitationObservational study
Retinal OCT Changes and Biomarkers in Drug-Resistant Epilepsy
Epilepsy (Treatment Refractory), Epilepsy
RecruitingPhase 2
Lumacaftor Yields Reversal of Impaired Cerebral Blood Flow in Heart Failure Patients
Heart Failure With Reduced Ejection Fraction
Enrolling by invitationPhase 2
Inhaled Nitric Oxide for Microvascular Dysfunction in Traumatic Brain Injury
Traumatic Brain Injury
RecruitingObservational study
Brain Health in Youth With Normal Weight, Overweight and Obesity at Risk for Type 2 Diabetes (T2D)
Type2 Diabetes, Type 2 Diabetes Mellitus in Obese
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Yilong Wang, MD, PhD principal investigator
Beijing Tiantan Hospital
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cerebral Microvascular Dysfunction and Cerebral Small Vessel Diseases, run by Beijing Tiantan Hospital at 2 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 6 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Yuesong Pan, PhD (010-59975807, panys2000@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cerebral small vessel disease (time frame: 2024-09 to 2032-09). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jan 2025.